Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Carbone

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
American Journal of Clinical Oncology|February 24, 2001
Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrinD I Rosenthal, C R Becerra, R D Toto, et al.
Nature Genetics|June 1, 1996
A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancerH L Chen, D Gabrilovich, R Tampé, et al.
Blood|December 3, 1998
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivoD Gabrilovich, T Ishida, T Oyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1998
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cellsT Oyama, S Ran, T Ishida, et al.
British Journal of Cancer|July 22, 2004
Nuclear survivin as a biomarker for non-small-cell lung cancerB Lu, A Gonzalez, P P Massion, et al.
Clinical and Experimental Immunology|August 12, 1999
Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responsesT Ishida, S Chada, M Stipanov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 1999
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivoJ E Ohm, M R Shurin, C Esche, et al.
Cancer Research|August 1, 1992
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutationS F Winter, J D Minna, B E Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2019
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptomsB L Andersen, T R Valentine, S B Lo, et al.
International Journal of Cancer|June 16, 2001
Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancerY Adachi, F Itoh, H Yamamoto, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
American Journal of Clinical Oncology|February 24, 2001
Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrinD I Rosenthal, C R Becerra, R D Toto, et al.
Nature Genetics|June 1, 1996
A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancerH L Chen, D Gabrilovich, R Tampé, et al.
Blood|December 3, 1998
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivoD Gabrilovich, T Ishida, T Oyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1998
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cellsT Oyama, S Ran, T Ishida, et al.
British Journal of Cancer|July 22, 2004
Nuclear survivin as a biomarker for non-small-cell lung cancerB Lu, A Gonzalez, P P Massion, et al.
Clinical and Experimental Immunology|August 12, 1999
Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responsesT Ishida, S Chada, M Stipanov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 1999
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivoJ E Ohm, M R Shurin, C Esche, et al.
Cancer Research|August 1, 1992
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutationS F Winter, J D Minna, B E Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2019
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptomsB L Andersen, T R Valentine, S B Lo, et al.
International Journal of Cancer|June 16, 2001
Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancerY Adachi, F Itoh, H Yamamoto, et al.
Pageof 10